0001683168-25-008328
SEC filingSunshine Biopharma's MD&A shows 11.6% quarterly revenue growth driven by generic drug sales, but operating losses persist due to a $554,650 intangible asset impairment.
For the three months ended September 30, 2025, Sunshine Biopharma generated $9,417,179 in revenue, an 11.6% increase from $8,435,178 in the prior-year quarter. This growth was attributed to enhanced marketing efforts for its generic drug portfolio. The direct cost of sales rose to $6,343,639 (67.4% of revenue) from $5,569,027 (66.0%), driven by increased costs for finished products. Consequently, gross profit increased by $207,389 to $3,073,540, though the gross margin contracted to 32.6% from 34.0%.
General and administrative expenses increased by $187,649 to $4,160,153. A significant driver was a $554,650 impairment charge for intangible assets related to product licenses deemed non-commercializable. This was partially offset by decreases in consulting fees, marketing, and salaries. The operating loss was $1,086,613, largely unchanged from the $1,106,353 loss in Q3 2024. After accounting for lower interest income of $75,352, the net loss was $883,820, a 24.0% improvement from a net loss of $1,197,803 in the prior year. EPS improved to a loss of $0.19 per share from a loss of $0.94.
For the nine months ended September 30, 2025, revenue was $27,728,750, a 9.7% increase from $25,279,291. Gross profit rose to $9,226,832, with the gross margin improving to 33.3% from 30.0% due to better procurement costs. However, a $1,616,459 impairment of intangible assets and higher consulting and salary expenses drove a $2,312,706 increase in G&A, leading to an operating loss of $4,437,018. The nine-month net loss was $3,834,425, or $0.98 per share.
The company operates through its wholly owned subsidiary, Nora Pharma, which markets 76 generic prescription drugs in Canada. The commercial strategy relies on in-licensing, cross-licensing, and distribution agreements. The MD&A highlights a pipeline of 12 additional drugs anticipated for launch in 2026, targeting a $9.7 billion Canadian generic drug market. The proprietary drug development segment, focused on K1.1 mRNA for liver cancer and SBFM-PL4 for coronavirus, remains in the animal testing stage and does not contribute to revenue.
Management is focused on achieving breakeven by increasing sales, streamlining operations, and reducing the cost of goods sold from approximately 67% to 60%. The company believes its existing cash on hand of $9.3 million, combined with sales revenue, will be sufficient to fund operations for the next 24 months. However, it acknowledges the need to raise additional capital in the future for R&D, potential clinical trials, and expansion. The Board's previously announced plan to invest $5 million in Bitcoin was abandoned due to market volatility.
As of September 30, 2025, Sunshine Biopharma reported total assets of $31.5 million, up from $30.6 million at year-end 2024. Cash and cash equivalents decreased to $9.3 million from $9.7 million, while inventory grew to $14.1 million (net of a $540,486 allowance for obsolete inventory) from $11.3 million. Total liabilities were $7.3 million, consisting primarily of accounts payable and accrued expenses ($6.1 million) and operating lease liabilities ($0.9 million). The company carries no long-term debt. Shareholders’ equity stood at $24.2 million, reflecting an accumulated deficit of $72.9 million. The current ratio was approximately 4.2:1, indicating strong short-term liquidity.
The Notes disclose operating lease obligations for office and warehouse space with a remaining term of 4 years and 3 months. Total undiscounted future lease payments are $854,746, with $322,905 due within one year, $413,577 in years two and three, and $180,868 beyond three years. A right-of-use asset of $820,489 and corresponding lease liabilities of $854,761 are recorded on the balance sheet. A disputed earnout payable of $295,797 (CAD $479,208) remains related to the Nora Pharma acquisition, though the former subsidiary president has demanded $5.3 million; management considers the claim unfounded and has not accrued any additional liability.
The company declared no dividends since inception. During the nine months ended September 30, 2025, investing activities used $786,097, including $620,817 for intangible asset purchases (product licenses) and $175,530 for equipment. Financing activities provided $4.0 million, driven by $2.2 million from warrant exercises and $1.8 million net proceeds from a registered direct offering of 1,188,404 shares and pre-funded warrants. In the prior year period, the company repurchased warrants for $3.1 million. No share buyback program is disclosed.
Sunshine Biopharma operates as a single business segment through two Canadian subsidiaries: Nora Pharma (76 generic prescription drugs) and Sunshine Biopharma Canada (OTC supplements). OTC supplement sales represent less than 3% of total sales. Revenue is generated primarily from sales to pharmacies across multiple Canadian provinces, with no material customer concentration risk. The company is also developing proprietary drugs (K1.1 mRNA for liver cancer and SBFM-PL4 for SARS-CoV-2), though no revenue is attributed to these programs.
For the nine months ended September 30, 2025, Sunshine Biopharma reported a net loss of $3.8M, while operating cash flow was a negative $3.7M. The near parity between net loss and operating cash flow indicates that non-cash charges and working capital changes largely offset each other. A significant non-cash item was a $1.6M intangible asset impairment, which depressed net income but did not impact cash. This was partially offset by a $2.4M build-up in inventory, a substantial use of cash. The prior year period included a $2.5M earn-out payment, making the year-over-year improvement in operating cash flow appear more dramatic.
Capital expenditures totaled $0.8M, with $0.6M allocated to intangible assets and $0.2M to equipment. The company does not report free cash flow, but combining operating and investing cash flows results in a cash burn of approximately $4.5M. This deficit was entirely funded by financing activities, which provided $4.0M through a public offering ($1.8M) and warrant exercises ($2.2M). Notably, the company did not repurchase any shares in the current period, compared to $3.1M in the prior year. No dividends were paid. The company's cash position remains adequate at $9.3M, though it declined by $0.5M during the period after accounting for a small positive foreign currency translation adjustment.